key: cord-0920112-17zzmh3k
authors: Wang, Di; Mao, Xia; Que, Yimei; Xu, Menglei; Cheng, Yuhang; Huang, Liang; Wang, Jue; Xiao, Yi; Wang, Wen; Hu, Guang; Zhang, Shangkun; Zhang, Tongcun; Li, Chunrui; Zhou, Jianfeng
title: Viral infection/reactivation during long-term follow-up in multiple myeloma patients with anti-BCMA CAR therapy
date: 2021-10-18
journal: Blood Cancer J
DOI: 10.1038/s41408-021-00563-8
sha: 1e50a77e4bf4aaf363eddfea1bc8fd5e648f3225
doc_id: 920112
cord_uid: 17zzmh3k

nan

The general characteristics of the participants are shown in Table S1 . The patients had a median age of 55.0 (range, 34.0-70.0) years and a median time from diagnosis of 37.0 (range, 8.0-151.0) months. Of the patients, 41.0% had a high-risk cytogenetic profile, and 41.0% had extra-medullary myeloma or plasma cell leukemia. The median line of therapies before enrollment was 4 (range, [3] [4] [5] [6] [7] [8] [9] [10] [11] . Viral infection/reactivation events were recorded separately before and after infusion, as summarized in Fig. 1A . There were ten viral DNA replication events in nine patients recorded before infusion. In the meantime, a total of 18 viral infection/reactivation events were recorded in 15 patients after infusion, including four EBV, six CMV, three HBV, four herpes zoster, and one COVID-19. The rate of viral infection/reactivation observed post infusion was significantly higher than that in published studies involving myeloma patients with chemotherapy [9, 10] , indicating that anti-BCMA CAR can negatively affect the anti-viral immunity.

CMV and EBV are members of the Herpesviridae family and can persist life-long as a latent infection in B cells and monocytes following the acute phase of infection. When the immune response is compromised by immunosuppressive therapies, both CMV and EBV can reactivate and cause clinical disease. One patient had detectable CMV DNA at screening without clinical symptoms and was treated prior to infusion. Six patients had CMV reactivation with a median load of 4.54 × 10 3 (range, 1.85 × 10 2 -5.06 × 10 4 ) copies/mL after anti-BCMA CAR infusion, including three symptomatic and three asymptomatic reactivations (Table S2 ). All reactivation events occurred in the first 6 months post infusion (Fig. S2) , and were treated preemptively with ganciclovir and immunoglobulin. The median time from reactivation diagnosis to CMV DNA negativity in peripheral blood was 26 days (range, 10-57). As shown in Fig.  S3 , EBV DNA replication was detected in eight patients at baseline with a median load of 1.1 × 10 3 (range, 6.96 × 10 2 -3.0 × 10 4 ) copies/mL. Interestingly, although no anti-EBV intervention was given, all the pre-existing EBV infections were automatically eradicated within 2 months post infusion. This phenomenon is probably because of the elimination of EBV-infected B cells by the on-target off-tumor effect of anti-BCMA CAR. Four patients had EBV reactivation after infusion, which were all asymptomatic. Two reactivation events were detected at the time of relapse or disease progression, one of which was eliminated by following fully human-originate CAR (Fig. S3) . None of the four asymptomatic patients received anti-EBV therapy. Notably, more CMV reactivations were observed in patients treated with glucocorticoids, while fewer EBV reactivations were found in glucocorticoid-treated patients (Table S3) .

As China is one of the epidemic areas of HBV, effective screening and drug prophylaxis in HBV-infected patients are essential for the participants. At screening, resolved HBV infection was detected in 47.5% (29/61) of the patients. Four patients (6.45%) had chronic HBV infection and were given entecavir as prophylaxis, among which one (patient 07) had active HBV DNA replication (Table S4) . HBV reactivation was observed in three patients (Fig. S4) , including patient 07, whose HBV DNA copies significantly increased post infusion and peaked at 1.23 × 10 5 IU/ mL at day 49. Another chronic infection (patient 28) had peak DNA copies at the first month post infusion. It is worth noting that one resolved infection (patient 14) who had no prophylaxis treatment encountered reactivation 6 months post infusion, and was finally controlled by entecavir. This case indicates that resolved-infection patients also need drug prophylaxis after anti-BCMA CAR treatment; otherwise, there is a risk of viral reactivation or even fulminant hepatitis.

One patient who achieved stringent complete response was infected by COVID-19 2 months post infusion. The patient was admitted to intensive care unit and received multiple antiviral therapies including umifenovir, lopinavir/ritonavir, and intravenous immunoglobulin. The immune system failed to generate neutralizing antibodies to prevent COVID-19 proliferation. Unfortunately, he passed away 28 days after diagnosis of COVID-19, as described by Wei et al. [11] . Herpes zoster was reported in four patients who did not receive any antiviral prophylaxis after CAR therapy. The onset time varied from 1 to 3 months post infusion, and the patients were cured with antiviral agents such as acyclovir or valaciclovir.

We monitored CAR transgene copy, lymphocyte subset, and serum immunoglobulin level at serial points post infusion. As shown in Fig. 1B , the percentage of total T cells kept increasing for 3 months to the peak, representing the expansion of CAR-T cells. The percentage of B cells and NK cells tended to decline post infusion, and the nadir of B cells occurred at 1 month. Till the data cut-off, B-cell recovery was observed only in 25 patients, with a median time of 4 (range, 1-10) months (Fig. S5) . We also monitored the CAR transgene copy. The peak arose within 1 month, which was parallel with the nadir of B cells. Meanwhile, the decrease of immunoglobulin lagged behind the B-cell depletion. The minimum of immunoglobulin level emerged at the third month post infusion, and hypogammaglobulinemia persisted for about 6 months (Fig. 1C) . This long-term abnormality in lymphocyte subsets and hypogammaglobulinemia demonstrated a profound negative impact on the immune system by BCMA-targeting.

Several measures can be taken to diminish the adverse effect of BCMA-targeting on viral immunity, as outlined in Fig. 1D . Firstly, a thorough screening test for viruses is recommended before lymphodepletion. CAR-T infusion would be postponed until treatment and eradication of any baseline active viral reactivations/infections, except for EBV. Also, viruses such as CMV and HBV need regular monitoring post infusion, since their reactivation may negatively affect survival [12] . Secondly, prophylactic antiviral therapy is essential [8] . Oral antiviral agent, such as acyclovir, is recommended after neutrocyte recovery. For CMV, more aggressive monitoring and prompt treatment after positive detection is recommended, as acyclovir may not be enough. We also suggest that both resolved and chronic HBV infections use anti-HBV drug such as entecavir from screening [13] . Thirdly, according to the hypogammaglobulinemia recovery curve, regular immunoglobulin infusion is preferred [8, 14] . But vaccination, especially attenuated live vaccine, is not recommended in the first 6 months since antibody synthesis is paralyzed [8, 15] . Lastly, reactivations of CMV, HBV, and other symptomatic viral infections detected post infusion would need immediate intervention to reduce the potential negative impact on survival (Fig. S6) .

In summary, viral infection/reactivations are common adverse events in patients receiving anti-BCMA CAR therapy because of persistent B-cell aplasia and hypogammaglobulinemia. Therefore, prophylaxis and regular monitoring of the virus are recommended. Since this retrospective study was limited to a relatively small sample size, and some infections might be underreported by the patients during the long-term follow-up, a prospective study of a larger scale is required in the future.

T cells genetically modified to express an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of poor-prognosis relapsed multiple myeloma

Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma

Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study

A phase I study of anti-BCMA CAR T cell therapy in relapsed/refractory multiple myeloma and plasma cell leukemia

A phase 1 study of a novel fully human BCMA-targeting CAR (CT103A) in patients with relapsed/refractory multiple myeloma

Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival

Infectious complications of CD19-targeted chimeric antigen receptor-modified T-cell immunotherapy

How I prevent infections in patients receiving CD19-targeted chimeric antigen receptor T cells for B-cell malignancies

Infections in patients with multiple myeloma in the era of high-dose therapy and novel agents

Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients

SARS-CoV-2 infection in immunocompromised patients: humoral versus cell-mediated immunity

Early cytomegalovirus reactivation remains associated with increased transplantrelated mortality in the current era: a CIBMTR analysis

Entecavir prophylaxis for hepatitis B virus reactivation in patients with CAR T-cell therapy

CAR-T -and a side order of IgG, to go? -Immunoglobulin replacement in patients receiving CAR-T cell therapy

Antibodies to vaccine preventable infections after CAR-T-cell therapy for B-cell malignancies

We thank all the faculty and staff in the Clinical and Laboratory Unit of the Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology for their clinical and technical supports. We thank all the staff in Nanjing IASO Therapeutics Ltd. and Wuhan Bio-Raid Biotechnology Co. Ltd. for their technical supports. This work was supported by the funding from the National Natural Science Foundation of China (81873452 and  82170223 

G.H. and J.Z. are among inventors of patent applications related to the CT103A. W.W. and G.H. are employees of Nanjing IASO Therapeutics Ltd. and held interests in the company. J.Z. is a nonpaid member of the Scientific and Medical Advisory Board of Nanjing IASO Therapeutics Ltd. S.Z. and T.Z. are employees of Wuhan Bio-Raid Biotechnology Co., Ltd. and held interests in the company. All other authors declare no competing interests.

Supplementary information The online version contains supplementary material available at https://doi.org/10.1038/s41408-021-00563-8.Correspondence and requests for materials should be addressed to Chunrui Li or Jianfeng Zhou.Reprints and permission information is available at http://www.nature.com/ reprintsPublisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons. org/licenses/by/4.0/.